table network network 2
demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID-19 severe or critically
COVID-19 severe or critically
tocilizumab Veiga Rashad MARIPOSA Talaschian Sarhan Hamed Sarhan COVACTA ... CORIMUNO-TOCI-ICU ... CORIMUNO-TOCI-1 ... NCT04377750 ... REMAP-CAP ... Rosas ...

25 studies excluded by filtering options 1

5444 TOCI-RAF Study Group (Campochiaro), 2020 1130not a RCTrisk of bias not avaialble
5489 Rojas-Marte, 2020 1134not a RCThigh risk of bias
5522 Somers, 2020 1134not a RCThigh risk of bias
5528 Mathilde, 2020 1134not a RCThigh risk of bias
5529 Andrew, 2020 1130not a RCTrisk of bias not avaialble
5616 Biran, 2020 1133not a RCThigh risk of bias
5628 Rossotti, 2020 1134not a RCThigh risk of bias
5632 Holt, 2020 2130excludednot a RCTrisk of bias not avaialble
5672 Klopfenstein, 2020 2134excludednot a RCThigh risk of bias
5941 Zeng, 2020 0300selection pending
5965 Pereira, 2020 0990selection pending
6281 Roumier, 2020 0100selection pending
6282 Menzella, 2020 0130selection pending
6335 Ruiz-Antoran, 2020 0130selection pending
6414 Mikulska, 2020 0130selection pending
6418 Guaraldi, 2020 0130selection pending
6420 Potere, 2020 0200selection pending
6425 Roumier, 2020 0130selection pending
6429 Kewan, 2020 0130selection pending
6431 Moreno-Pérez, 2020 0130selection pending
6433 Canziani, 2020 0200selection pending
6435 Gokhale, 2020 0130selection pending
8509 Karampitsakos, 2021 0310selection pending
9133 Karakike (ESCAPE), 2021 0310selection pending
9225 Belhassen-Garc??a, 2021 0110selection pending

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons